6 results · Page 1 of 1

Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque PsoriasisPlaque PsoriasisActive, not recruitingPhase 32026-09-28NCT06143878
A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKEbrain disorder, cardiovascular disorder, central nervous system disorder, cerebrovascular disorder, ischemic stroke, nervous system disorder, stroke disorder, vascular disorderActive, not recruitingPhase 32026-09-25NCT05702034
A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the BladderFemale Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, benign urinary system neoplasm, neoplasm, urinary bladder disorder, urinary bladder neoplasm, urinary system disorderActive, not recruitingPhase 32026-09-25NCT04658862
A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate CancerGenital Diseases, Male Urogenital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, male reproductive organ cancer, male reproductive system disorder, neoplasm, prostate cancer, prostate disorderActive, not recruitingPhase 32026-09-25NCT04557059
A Study of Nipocalimab in Participants With Active Idiopathic Inflammatory Myopathiesmuscle tissue disorder, musculoskeletal system disorder, myositis disease, nervous system disorder, neuromuscular diseaseActive, not recruitingPhase 22026-09-21NCT05379634
A Study of Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) Treated With T-cell Redirectors Outside of Clinical TrialsBlood Protein Disorders, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic diseaseRecruitingNot stated2026-08-28NCT06285318